Skip to content
Terminus Peptides
  • Research use only — not for human or veterinary use
  • 55 compound profiles, every source cited
  • 62 research materials listed
  • Prices published, not hidden behind an enquiry
  • Vials and pre-filled pens
  • Dispatched and supported from the UK
  • Every profile states its UK regulatory status

Research profile · Peptide analogue

CJC-1295 without DAC

Also known as Modified GRF 1-29, Mod GRF 1-29

In vitro — evidence level 1 of 4: In-vitro evidenceExperimental — UK regulatory status: Experimental — not authorised for human use in the UK

Overview

A growth hormone-releasing hormone analogue lacking the albumin-binding moiety. It has no published study of its own at any evidence level.

Category
Peptide analogue
Highest evidence level identified
In-vitro evidence
Last scientifically reviewed
20 August 2026
Last regulatory review
20 August 2026

Mechanism under investigation

This form shares the modified growth hormone-releasing hormone core of CJC-1295 but lacks the drug affinity complex that binds it to serum albumin. It is therefore a pharmacologically distinct product with a much shorter expected duration of action, though its half-life has not been reported in any peer-reviewed human study. Its rationale is extrapolated from the shared core rather than established for the molecule itself.

Research areas

  • Pituitary endocrinology

These are fields in which the compound has been investigated. Listing a field is not a statement that anything was demonstrated within it.

Current evidence

In-vitro evidence

Cells, tissues or biochemical systems outside a living organism.

No dedicated published study was located for this molecule as distinct from the form carrying the albumin-binding moiety.

Animal evidence

Studies in living non-human animals.

No dedicated published study was located.

Human observational evidence

Studies observing people without assigning an intervention.

None. The molecule appears in the literature only as an analyte: it was identified among growth hormone secretagogues in seized doping material, which is forensic chemistry rather than evidence of any effect.

Clinical-trial evidence

Studies assigning an intervention to human participants.

None. A targeted search across the compound’s several names returned no human clinical trials. A 2026 review states that its half-life is not reported in human studies and that no peer-reviewed clinical studies in humans have reported even the route of administration.

Study limitations

  • The evidence level shown is the lowest the framework offers, and even that overstates the position: no dedicated study of this molecule was located at any level. It is recorded here as the floor of the scale, not as a finding that in vitro data exists.
  • The compound is routinely discussed as though the phase 1 data for the albumin-bound form applies to it. The two differ substantially in exposure profile and are not interchangeable.
  • No pharmacokinetic data of any kind has been published, so even the duration of action is unestablished.
  • Everything claimed for this molecule is extrapolation from the shared core sequence.

UK regulatory context

Experimental — not authorised for human use in the UK

A compound appearing in research literature that holds no UK authorisation for human use in any indication.

Source: The Human Medicines Regulations 2012, regulation 46 — prohibition on sale or supply of an unauthorised medicinal product (opens legislation.gov.uk in a new tab) (legislation.gov.uk)

Regulatory classification is jurisdiction-specific. A compound authorised elsewhere is not thereby authorised in the UK, and a supplier’s description of a substance does not determine how it is classified in law. See safety and regulation for the framework and the authoritative sources.

Safety and interpretation

There is no human safety data for this molecule at all — no trial, no pharmacokinetic characterisation, no systematic adverse-event reporting. Reasoning about it from the studies of the albumin-bound form is not supported, because the two produce quite different exposure over time.

References